Bay Street News, March 28th, 2025

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage […]

– Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity […]

– Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant […]

Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce […]

Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under “ATLN” Announces Strategic Developments and Outlook; Targets $1 to $1.5 […]

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered […]

TORONTO, March 28, 2025 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW) (“Flow Capital” or the “Company”), a leading provider of […]

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that […]

RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional […]

– Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) – [...]